secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aspira Women's Health Inc. (AWHL)
CIK:        0000926617
Form:       8-K/A
Filed at:   2026-03-25T23:59:59+00:00
Accession:  0000926617-26-000012
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aspira enters lab services pact with Mayo Clinic for Ova1Plus and OvaWatch tests
--------------------------------------------------------------------------------

- Agreement effective Dec 16, 2025; Mayo will list Aspira’s Ova1Plus and OvaWatch in its test catalog.
- Mayo obligated to set minimum list prices (redacted); will market tests to its clients.
- Initial term (redacted years) with automatic renewal; either party may terminate without cause on (redacted) days notice.
- Testing is non-exclusive and on an as-requested basis; many financial terms remain confidential.
- Partnership leverages Mayo’s national distribution to expand reach of Aspira’s ovarian cancer tests.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/926617/000092661726000012/0000926617-26-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/926617/000092661726000012/awhl-20251223x8ka.htm
  HTML page:      https://secwatch.observer/filing/0000926617-26-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer